| Management target | Revenue 18.0% Next 3-4 Years |
|---|
| Margins | EBITDA margins rising towards 25% target. |
|---|---|
| Order book | 57 active CDMO projects; 37 in commercial stage. |
| Demand visibility | Strong growth in CDMO and Xanthine segments. |
| Management confidence | High |
Growth
Q1FY27 Revenue grew 38.7% YoY; PAT grew 65.4% YoY. Standalone EBITDA margins reached 24.82%.
Outlook
Targeting 15-18% Revenue and EBITDA CAGR over next 3-4 years. Brownfield CDMO capex planned for H2FY28.
Risks
Geopolitical tensions keeping raw material prices elevated; temporary shutdown at Unit 4 impacted Steroid production.
Last quarter's promises, checked
Delivered
- Targeted 15-18% Revenue/EBITDA CAGR → delivered 38.7% Rev growth (= BEAT)
- Expected CDMO growth 40-50% → delivered 57 active projects/robust growth (= BEAT)
- Xanthine capacity expansion to 9,000 MTPA → incremental capacity available (= BEAT)
Partly delivered
- Atali Phase 1 operational by Q1FY27 → Phase 1 operational but Block 2 capex ongoing (= PARTIAL)
Missed
- API Segment to surpass FY25 (Rs.700-770 Cr) → Segment impacted by Unit 4 shutdown (= MISS)
Investor Presentation filed with BSE, NSE: AARTIPHARM. Summary written with AI assistance from the document.
Aarti Pharmalabs Ltd: key numbers
- Share price
- ₹939.55
- Market cap
- ₹8,520 Cr
- Revenue (annual)
- ₹1,819 Cr
- Net profit (annual)
- ₹174.7 Cr
- P/E (TTM)
- 40.0×Sector 50.4×
- Promoter holding
- 42.86%-0.22% QoQ
- FII holding
- 8.17%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aarti Pharmalabs Ltd
All →Aarti Pharmalabs Promoter Selling: ₹106.4 Cr
Promoters sold a total of 15.12 lakh shares via open market transactions, aggregating to ₹106.43 Crore.
- Value
- ₹106.4 Cr
Aarti Pharmalabs Management Change
Aarti Pharmalabs reported directorate changes, including Shri Rashesh Gogri's appointment as Managing Director, Smt. Hetal Gogri Gala's re-designation, and the cessation of Shri Rajendra Gogri.
Aarti Pharmalabs Promoter Selling
Aarti Pharmalabs promoters sold a net 29.03 lakh shares, reducing their stake from 42.88% to 39.66%. No transaction value is disclosed in this periodic SAST filing.
Aarti Pharmalabs Investor Presentation: Key Takeaways
7th AGM presentation for Aarti Pharmalabs. Reported Standalone FY26 Revenue of INR 1,798 Cr with 23% EBITDA margin; Consolidated revenue down 14% YoY to INR 1,819 Cr.
- Call
- Guides 18% growth
Aarti Pharmalabs Annual General Meeting
Aarti Pharmalabs conducted its 7th Annual General Meeting on September 22, 2026, to transact ordinary and special business, with voting results to follow.
Aarti Pharmalabs Promoter Selling: ₹10.43 Cr
Promoter Group entities, Safechem Enterprises and Relacion Trusteeship, sold 1,19,400 shares of Aarti Pharmalabs in the open market for a total of ₹10.43 Crore.
- Value
- ₹10.43 Cr